Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.

IF 2.7 4区医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI:10.1080/1750743X.2024.2370231

Beliz Bahar Karaoğlan, Emre Yekedüz, Satı Coşkun Yazgan, Eda Eylemer Mocan, Elif Berna Köksoy, Hatime Arzu Yaşar, Filiz Çay Şenler, Güngör Utkan, Ahmet Demirkazık, Hakan Akbulut, Yüksel Ürün

{"title":"Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.","authors":"Beliz Bahar Karaoğlan, Emre Yekedüz, Satı Coşkun Yazgan, Eda Eylemer Mocan, Elif Berna Köksoy, Hatime Arzu Yaşar, Filiz Çay Şenler, Güngör Utkan, Ahmet Demirkazık, Hakan Akbulut, Yüksel Ürün","doi":"10.1080/1750743X.2024.2370231","DOIUrl":null,"url":null,"abstract":"Background: Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear.Objective: Assessing the association of pre- and post-ICI treatment sodium levels with survival.Methods: We retrospectively analyzed patients receiving ICI in January 2012-December 2023, collecting serum sodium levels at treatment initiation and 4 weeks post-ICI, with overall survival (OS) as the primary outcome.Results: Low sodium was observed in 125 and 119 patients pre-and post-treatment respectively. Pre-ICI and post-ICI low sodium correlated with decreased OS [10.6 vs. 22.9 months (p = 0.001) and 11.6 vs. 27.2 months (p = 0.009)]. Multivariate analysis identified pre-ICI low sodium [HR: 1.685; 95% CI: 1.050-2.705; p = 0.031] as an independent risk factor for worse OS.Conclusion: Low baseline serum sodium was an independent risk factor for poor OS in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"821-828"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457628/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2370231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear.Objective: Assessing the association of pre- and post-ICI treatment sodium levels with survival.Methods: We retrospectively analyzed patients receiving ICI in January 2012-December 2023, collecting serum sodium levels at treatment initiation and 4 weeks post-ICI, with overall survival (OS) as the primary outcome.Results: Low sodium was observed in 125 and 119 patients pre-and post-treatment respectively. Pre-ICI and post-ICI low sodium correlated with decreased OS [10.6 vs. 22.9 months (p = 0.001) and 11.6 vs. 27.2 months (p = 0.009)]. Multivariate analysis identified pre-ICI low sodium [HR: 1.685; 95% CI: 1.050-2.705; p = 0.031] as an independent risk factor for worse OS.Conclusion: Low baseline serum sodium was an independent risk factor for poor OS in patients treated with ICIs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

低钠值对接受免疫检查点抑制剂的癌症患者生存结果的影响。

背景：低血清钠会影响癌症预后，但其对免疫疗法的影响尚不明确。目的：评估国际癌症研究所治疗前后钠水平与生存期的关系：评估国际癌症研究所治疗前后钠水平与生存的关系。方法我们回顾性分析了 2012 年 1 月至 2023 年 12 月接受 ICI 的患者，收集了治疗开始时和 ICI 后 4 周的血清钠水平，并将总生存期（OS）作为主要结果。结果显示治疗前和治疗后分别有125名和119名患者出现低血钠。ICI前和ICI后低钠与OS下降相关[10.6个月 vs. 22.9个月 (p = 0.001) 和 11.6个月 vs. 27.2个月 (p = 0.009)]。多变量分析发现，ICI 前的低钠[HR：1.685；95% CI：1.050-2.705；p = 0.031]是导致 OS 下降的独立风险因素。结论基线血清钠过低是 ICIs 治疗患者 OS 差的独立风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.